Dr. Larry Borish
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- Medical school
- Boston University School of Medicine (1979)
- Years since graduation
- 47
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 98
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1979Medical school: Boston University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
VA license 0101222026
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Virginia Medical Center Charlottesville, VA
Medical groups
- University of Virginia Physicians Group (1,717 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 98
- Services billed
- 167
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 69 | 53 |
| Test to measure expiratory airflow and volume | 25 | 18 |
| New patient office or other outpatient visit, 45-59 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hizentra (immun glob g(igg)/pro/iga 0-50) | 41 |
| Dupixent Pen (dupilumab) Other prescribers in Charlottesville, VA | 39 |
| Prednisone Other prescribers in Charlottesville, VA | 32 |
| Azelastine Hcl Other prescribers in Charlottesville, VA | 22 |
| Omeprazole Other prescribers in Charlottesville, VA | 22 |
| Montelukast Sodium Other prescribers in Charlottesville, VA | 17 |
| Ipratropium Bromide Other prescribers in Charlottesville, VA | 15 |
| Budesonide-Formoterol Fumarate (budesonide/formoterol fumarate) Other prescribers in Charlottesville, VA | 14 |
| Hydroxychloroquine Sulfate Other prescribers in Charlottesville, VA | 14 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Charlottesville, VA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 10 payments worth $10,530 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $10,307 |
|---|---|
| GlaxoSmithKline, LLC. | $88.97 |
| AstraZeneca Pharmaceuticals LP | $67.51 |
| Pharming Healthcare, Inc. | $40.00 |
| Regeneron Pharmaceuticals, Inc. | $26.41 |
| Consulting Fee | $9,000 |
|---|---|
| Travel and Lodging | $1,041 |
| Food and Beverage | $469 |
| Education | $19.31 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation May 2, 2025 | Consulting Fee | $9,000 |
| Novartis Pharmaceuticals Corporation May 2, 2025 | Travel and Lodging travel to EAST HANOVER, NJ | $813 |
| Novartis Pharmaceuticals Corporation May 2, 2025 | Travel and Lodging travel to EAST HANOVER, NJ · in-kind | $228 |
| Novartis Pharmaceuticals Corporation May 1, 2025 | Education in-kind | $19.31 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $247,963 in research payments for these studies, mostly to the institutions running them.
- A randomized, placebo-controlled study to assess cellular and molecular markers related to experimental rhinovirus infection in mild asthmatics, and the effect of dupilumab in this investigational model
Regeneron Pharmaceuticals, Inc. - Congenital Athymia Patient Registry
Sumitomo Pharma America, Inc. · Recruiting · NCT05329935 - Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT04959448
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.